Hims stock toppled late Monday after a steeper-than-expected loss outweighed its second-quarter sales beat and raise. The company, known for its telehealth platform and knockoff versions of Novo Nordisk’s (NVO) injectable semaglutide, reported a 37-cent per-share loss during the June quarter. Analysts expected a lighter 5-cent loss per share. That led Hims & Hers Health (HIMS) shares to topple more…
Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
Related news
Hims, The Surprise Winner Of The FDA Showdown With Peptides, Bounds Higher
7/23/2026 Hims stock bounded higher Thursday after an FDA panel recommended compounding a popular peptide used in injury recovery.
7/23/2026 Hims stock bounded higher Thursday after an FDA panel recommended…
